Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)

Sponsor
Candid Therapeutics
Study ID
NCT07215650
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Generalized Myasthenia Gravis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cizutamig — DRUG
    Cizutamig will be dosed according to the protocol

Study Details

The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of Cizutamig in patients with Generalized Myasthenia Gravis.

Key Dates

First listed
Oct 10, 2025
Start date
Sep 16, 2025
Status verified
Nov 2025
Primary completion
Dec 31, 2027
Completion
Apr 30, 2028

Study Design

Enrollment
44 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cizutamig

Primary Outcome Measure

Incidence and severity of treatment-emergent adverse events through end of study [ Time Frame: Baseline to Month 12 ]

Central Contacts

Related Studies